Inactive Instrument

THES ACQU

Equities

RACA

US88339T1034

Biotechnology & Medical Research

Therapeutics Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2021

April 29, 2021 at 12:41 pm EDT

Therapeutics Acquisition Corp. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced operating loss was USD 1.402 million. Net loss was USD 1.399 million.

Latest news about THES ACQU

Therapeutics Acquisition Corp.(NasdaqCM:RACA) dropped from NASDAQ Composite Index	21-06-30	CI
Point Biopharma Inc. completed the acquisition of Therapeutics Acquisition Corp. from Therapeutics Acquisition Holdings LLC and other shareholders in a reverse merger transaction.	21-06-29	CI
POINT Biopharma Announces First Patients Dosed in Phase 3 Study of PNT2002 for mCRPC	21-06-04	CI
Therapeutics Acquisition : Point Biopharma Phase 3 Trial for Cancer Therapy Doses First Patient Group	21-06-04	MT
Therapeutics Acquisition Corp. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-04-29	CI
Merck : Completes Pandion Therapeutics Acquisition	21-04-01	MT
Therapeutics Acquisition : POINT Biopharma To Go Public Via SPAC Combination	21-03-15	MT
Point Biopharma Inc. entered into a non-binding letter of intent to acquire Therapeutics Acquisition Corp. from Therapeutics Acquisition Holdings LLC and other shareholders in a reverse merger transaction.	21-03-14	CI
Therapeutics Acquisition Corp.(NasdaqCM:RACA) added to NASDAQ Composite Index	20-07-09	CI
Therapeutics Acquisition Corp. has completed an IPO in the amount of $118 million.	20-07-08	CI
Certain Class B Common Stock of Therapeutics Acquisition Corp. are subject to a Lock-Up Agreement Ending on 5-JAN-2021.	20-07-08	CI
Therapeutics Acquisition Corp. has filed an IPO in the amount of $100 million.	20-06-15	CI

Chart THES ACQU

Duration

Period

More charts

Company Profile

POINT Biopharma Inc., formerly Therapeutics Acquisition Corp, is a late-stage clinical precision oncology company. The Company focuses on developing and commercializing radiopharmaceuticals for the treatment of cancer. Its pipeline programs include lutetium-177 and actinium-225. The Company's product candidates include PNT2002 and PNT2003 for the treatment of prostate cancer and neuroendocrine tumors. PNT2002 is a prostate-specific membrane antigen (PSMA), targeted radioligand is in Phase III trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC). PNT2002 combines a PSMA-specific ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177 (177Lu-PSMA-I&T). PNT2003 is a somatostatin-targeted radioligand in development for the treatment of neuroendocrine tumors. PNT2003 combines a somatostatin-specific radioligand DOTATATE with lutetium-177 (177Lu-DOTATATE).

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
REGENERON PHARMACEUTICALS, INC.	+9.15%	105B
VERTEX PHARMACEUTICALS INCORPORATED	-1.08%	104B
ARGENX SE	+5.79%	22.94B
BIONTECH SE	-11.55%	22.34B
GENMAB A/S	-7.01%	19.25B
WUXI APPTEC CO., LTD.	-37.08%	17.08B
BEIGENE, LTD.	-9.91%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+7.55%	14.16B
SAREPTA THERAPEUTICS, INC.	+40.04%	12.63B

Bio Therapeutic Drugs